Slingshot members are tracking this event:

Amgen's (AMGN) BLINCYTO earns FDA approval for relasped or refractory B-cell acute lymphoblastic leukemia

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMGN Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2017
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Blincyto, Fda Approval, Relapsed/refractory Acute Lymphoblastic Leuke